Session

Overview: Both the radiation modality and the way of dose delivery play a role in tissue response. The preclinical data demonstrated that FLASH delivery of the different types of radiation at ultra-high dose rates (>30-40 Gy/s) and conventional radiotherapy have similar anti-tumor responses; however, FLASH radiotherapy has less normal tissue toxicity. On the other hand, preclinical and clinical evidence suggests that particle therapy has more precise dose delivery and, therefore, may achieve a higher therapeutic efficacy than photon-based treatment. This debate session will argue whether FLASH radiotherapy is a more promising avenue for the future of radiation oncology than particle radiotherapy and discuss its immunomodulatory effects and limitations on the way to clinical translation.